Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
Rajesh Pahwa(University of Kansas Medical Center), James H. Sherry(Ironwood Pharmaceuticals (United States)), William C. Koller(Stanford University), Richard Trosch(Parkinson's and Movement Disorder Institute)
Cited by 89
Related Papers
Variable expression of Parkinson's disease
|Neurology|1990|1.3k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
|The American Journal of Human Genetics|2003|537
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
|Annals of Neurology|1997|484